Currently Viewing:
COA Community Oncology Conference 2019
Currently Reading
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Rose Gerber: Keep the Patient in Mind During Clinical Trials

Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.


Rose Gerber, director of patient advocacy and education for the Community Oncology Alliance, discusses the importance of patient education in encouraging clinical trial participation, as well as the importance of trials being patient centered.

Transcript

How important of a role does education play in encouraging clinical trial participation?

I think the education component is really important because when a patient is sitting in front of their doctor and they’re just having that simple dialogue, it’s building trust. Pretty much the entire population sees an oncologist or any doctor as a very competent individual. So, when they’re sitting there and their doctor is telling them about all the risks and benefits of a trial, I think that starts to put the patient’s mind at ease.

While clinical trials are important for collecting data on a drug, why is it important to make sure that trials are patient centered?

I think patient centricity is something that’s a buzz word right now, but really what it means is we really want to make sure that even though scientists have their goals and the goal of testing a new drug is to determine the outcomes, we need to remember there is a real live person this drug is being tested on and the person is not a robot; this is someone with a heart, feelings, emotions, and fears. Especially when you’re newly diagnosed, that’s when you’re the most vulnerable. So, anytime there’s a group of people planning a research study, whether these are the researchers or the oncologist, you need to really think of the patient because that’s actually who it’s going to impact—a real life human being.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up